Latest Developments

03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.

MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety

01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.

Current Stock Info

AFLB.OB0.00  chart+0.00
1970-01-01 00:00

Formulation Studies

Preformulation and Formulation Development

  • Excipient identification and compatibility studies
  • Physical property characterization
  • Formulation development
  • Pilot scale manufacturing
  • Process development and scale-up
  • Commercial formulation development